-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Nt2Y6yiYle/a1BN0YKf+jaTr0jy2ti/VsDszf6mTIhUoVp3kefEWZ8UAnxsHK9YA
 POW9l9LOjUQ4G5eQyL/bFw==

<SEC-DOCUMENT>0001144204-10-011091.txt : 20100303
<SEC-HEADER>0001144204-10-011091.hdr.sgml : 20100303
<ACCEPTANCE-DATETIME>20100302191051
ACCESSION NUMBER:		0001144204-10-011091
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20100302
FILED AS OF DATE:		20100303
DATE AS OF CHANGE:		20100302

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		10651048

	BUSINESS ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
		BUSINESS PHONE:		972-8-930-4440

	MAIL ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v176140_6k.htm
<TEXT>
<html>
  <head>
    <title>Unassociated Document</title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizer 4.0.6.1-->
    <!--Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved-->
    </head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNITED
STATES</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES
AND EXCHANGE COMMISSION</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Washington,
D.C. 20549</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
6-K</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Report
of Foreign Private Issuer</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to Rule 13a-16 or 15d-16</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of
the Securities Exchange Act of 1934</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the
month of March, 2010</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
File Number: <font style="DISPLAY: inline; FONT-WEIGHT: bold">000-51310</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: none">XTL Biopharmaceuticals
Ltd.</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    <div>
      <hr style="COLOR: black" align="center" noshade size="1" width="30%">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: none">(Translation
of registrant's name into English)</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Kiryat
Weizmann Science Park</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3
Hasapir Street, Building 3, PO Box 370</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: none">Rehovot 76100,
Israel</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
      <hr style="COLOR: black" align="center" noshade size="1" width="30%">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: none">(Address
of principal executive offices)</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div align="center">
      <table cellpadding="0" cellspacing="0" width="40%">
          <tr>
            <td valign="top" width="37%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form
      20-F&#160; <font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font></font></div>
            </td>
            <td valign="top" width="37%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form
      40-F&#160; <font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): ____</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): ____</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether by furnishing the information contained in this Form, the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div align="center">
      <table cellpadding="0" cellspacing="0" width="40%">
          <tr>
            <td valign="top" width="37%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Yes&#160;
      <font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
            </td>
            <td valign="top" width="37%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">No&#160;
      <font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If &#8220;Yes&#8221;
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-<font style="DISPLAY: inline; TEXT-DECORATION: underline"> N/Aa</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporation
by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated March 2, 2010
is hereby incorporated by reference into the registration statements on Form F-3
(File No. 333-141529, File No. 333-147024 and File No. 333-153055) filed by XTL
Biopharmaceuticals Ltd. with the Securities and Exchange Commission on March 23,
2007 , October 30, 2007 and August 15, 2008, respectively, and the registration
statements on Form S-8 (File No. 333-148085, File No. 333-148754 and File No.
333-154795) filed by XTL Biopharmaceuticals Ltd. with the Securities and
Exchange Commission on December 14, 2007, January 18, 2008, and October 28,
2008, respectively.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">XTL Biopharmaceuticals Announces The
Results Of Its</font> <font style="DISPLAY: inline; FONT-WEIGHT: bold">Extraordinary General Meeting and
Annual General Meeting</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Attached
below are statements relating to an Extraordinary General Meeting and the <font style="DISPLAY: inline; FONT-SIZE: 10pt">Annual General Meeting of XTL
</font>Biopharmaceuticals<font style="DISPLAY: inline; FONT-SIZE: 10pt">.</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 2
- -</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><img src="xtlbio.jpg" alt=""></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Extraordinary
General Meeting Statement</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Ramt Gan, Israel, March 2, 2010
</font>- XTL Biopharmaceuticals Ltd. <font style="DISPLAY: inline; FONT-SIZE: 10pt">(TASE: XTL, Pink Sheets:
XTLBY.PK)</font> ("XTL" or the &#8220;Company") announced the results of its
Extraordinary General Meeting of shareholders (the &#8220;EGM&#8221;) held on March 2,
2010.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At the
EGM, the proposal set forth in XTL's proxy statement dated February 1, 2010 (the
"Proxy Statement") sent in connection with the EGM, was approved by the required
majority of shareholders. The proposal was as follows:</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EGM
Resolution:</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
approval of the issuance of 133,063,688 ordinary shares, nominal value NIS 0.1
each, to all of the shareholders of XTEPO Ltd., pro rata to their shareholdings
in XTEPO Ltd., in consideration for the transfer to the Company of all such
shareholders&#8217; holdings in XTEPO Ltd.&#160;&#160;Following such transfer, the
Company shall own 100% of the shares of XTEPO Ltd. and the shareholders of XTEPO
Ltd. will own approximately 69.4% of the share capital of the
Company.</font></div>
    <div align="center">
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 3
- -</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman">Annual
General Meetings Statement</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font size="+0"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ramt
Gan, Israel, March 2, 2010 </font>- XTL Biopharmaceuticals Ltd. (TASE: XTL, Pink
Sheets: XTLBY.PK) <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">("XTL" or
the &#8220;Company") </font>announced today the results of its Annual General Meeting
of shareholders (&#8220;AGM&#8221;) held on March 2, 2010 in Ramt Gan, Israel. At the AGM,
all of the proposals set forth in XTL's proxy <font size="+0" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">statement dated
February </font>1, 2010 (the "Proxy Statement") sent in connection with the AGM
were approved by the required majority of shareholders. The proposals were as
follows:</font></font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AGM
resolutions:</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 18pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
      ratify the appointment of Kesselman &amp; Kesselman (PwC Israel) to serve
      as the Company&#8217;s auditors for the fiscal year 2009 and to empower the
      Company&#8217;s Board to determine their
fees.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 18pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
      approve the reappointment of Marc Allouche as a Director of the Company
      until the next Annual General
Meeting.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 18pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
      approve the reappointment of Amit Yonay as a Director of the Company until
      the next Annual General Meeting.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 18pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
      approve the reappointment of Boaz Shweiger as a Director of the Company
      until the next Annual General
Meeting.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 18pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
      approve the reappointment of David Grossman as a Director of the Company
      until the next Annual General
Meeting.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 18pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
      approve the terms of employment of Mr. David Grossman, the Company&#8217;s CEO
      and Director, including the grant of 1,610,000 registered non-marketable
      options, exercisable into Company
shares.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 18pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
      approve the grant of a letter of discharge from liability and undertaking
      to indemnify Company directors.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 18pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
      approve the grant of 150,000 non-marketable, registered options
      exercisable into Company shares to Marc
  Allouche.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 18pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
      approve the grant of 150,000 non-marketable, registered options
      exercisable into Company shares to Amit
Yonay.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 18pt">
            </td>
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
      approve the grant of 150,000 non-marketable, registered options
      exercisable into Company shares to Boaz
  Shweiger.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 4
- -</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Contact:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
Relations, XTL Biopharmaceuticals Ltd.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel: +972
3 612 7011, Email: ir@xtlbio.com</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cautionary
Statement</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Some of
the statements included in this Form 6-K may be forward-looking statements that
involve a number of risks and uncertainties. For those statements, we claim the
protection of the safe harbor for forward-looking statements contained in the
Private Securities Litigation Reform Act of 1995.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 5
- -</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td colspan="3" valign="top" width="38%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">XTL
      BIOPHARMACEUTICALS LTD.</font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="34%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
          </tr>
          <tr>
            <td valign="top" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="34%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
          </tr>
          <tr>
            <td valign="top" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="34%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
          </tr>
          <tr>
            <td valign="top" width="48%" style="PADDING-BOTTOM: 2px">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date:
      March 2, 2010</font></div>
            </td>
            <td valign="top" width="4%" style="PADDING-BOTTOM: 2px">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
            </td>
            <td valign="top" width="34%" style="PADDING-LEFT: 0pt; BORDER-BOTTOM: black 2px solid">
              <div style="MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/ <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">David
      Grossman</font></font></font></div>
            </td>
            <td valign="top" width="14%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
          </tr>
          <tr>
            <td valign="top" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="34%" style="PADDING-LEFT: 0pt">
              <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">David
      Grossman</font></div>
            </td>
            <td align="left" valign="top" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
          </tr>
          <tr>
            <td valign="top" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="34%" style="PADDING-LEFT: 0pt">
              <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief
      Executive Officer</font></div>
            </td>
            <td align="left" valign="top" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 6
- -</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>xtlbio.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 xtlbio.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X0S>17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````;````<@$R``(````4````C8=I``0````!````I````-````!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W,`,C`Q,#HP,SHP
M,B`Q.#HT-CHS,````````Z`!``,````!``$``*`"``0````!````EJ`#``0`
M```!````+@`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```NH````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B
M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`+@"6`P$B``(1`0,1`?_=``0`
M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`]4+FC0D3\5SGUZ^L>1T'HS;\(`Y.18*:
MWN&YK-'/=9M_.=M9[%A_XT/JV;J!U[$!]6@!F8UOYU?YEW_6?S_^#_XM<G]4
M,C"RKW_5_JQ<<#J3F['`P:LENE%U;CNV[Y]%3X\0,1.^(#YHTPSR$'@JK^63
MO?4CZ]=;RNMT]-ZG;]KIRR6M<6M:YCPUSVD>FUGL=M]R],WL_>'WKS7K71.D
M_47"?EXMUF1U?+#J,)]D#TFN&V^]C6!OO96[9O\`Y:YKZG?5ZWZP=79CN+AA
MTQ9EOD_0G2N?W[OHI\\<)W.)X(`=MUL9RA4#ZI'QV?;]S?$?>EO9^\/O7F/U
M]^K/7,WKPMZ9@V6XK,>JMAK@-&W=[![F_17*9WU;^L/3L9V5G8=M%#2`ZQQ$
M`N.UOT7%,C@C(`^X+/1=+-*)(X":ZOO.]G[P^]+>S]X?>OGS`P,_J60,7!J?
MD7D%PK:=8'TC[B%I'ZF?6T:GIM_WM_\`)IQY8#0Y`/Y>:T<P3J($ON.]G[P^
M]27SST\N_:.*"3_/U]_Y;5]#*/+B]NM;MDQ9..]*I2:1,3KX)UQ3"?\`GZ1.
MGJ'_`,](8L7'QZUP1,_\59GS^U[?IXO<R1Q;UP\?Z3VJ222C9UB0.3"=8?UH
MZ+E]7JQV8KF--3G%V\D:$`:;6N6I@4/Q\+'HL@OJK8QQ'$M`:83S&(A&0E<B
M3<?W6.,YG)*!@1&(!CDO2=]&PDDDF,BDDDDE/__0]3LK9;6ZJQH?6\%KVG4$
M$0YI7AWUM^K]OU>ZR_&9/V:S]+AV=]A/T=W^DI=[%[FO+?\`&GUW'R\NGH]#
M6O=A$OONY(>X1Z#'?U/=;_8_T:GY8RXZ&QW8>8`X+.XV>6ZKU;JGUCSZ'Y$W
M9&RO'IK;W(]OM'[]UGZ1Z]@^J7U=J^K_`$AF+H[)L_295@_.L/YH_D5?08O&
M>B]3MZ1U7&ZC6P/=COW%CARTC:]O\G<QWL>O><#.QNHX5.;BNWT9#0]CO(]C
M_*;]%RDYJP(Q`J"SEZ)E(FY-A<K_`(S/_$ED?\93_P!6U=4N5_QF?^)+(_XR
MG_JVJOB_G(^89\GR2\B\-_BQ_P#%97_Q%OY&KV%_T'?`KQ[_`!8_^*RO_B+?
MR-7L+_H.^!4G-?SGT#'R_P#-_4OSW@?\I8W_`(8K_P"K:OH9?/.!_P`I8W_A
MBO\`ZMJ^AD_F]X_5;RVTO-2X#J.<.G_6Z_,+=_I.)#!I)-6QO_2<N_7!Y-#,
MCZ[^D\2TWM)'CM8VS_OJ7)UQ9.+4>W*_)@^)<7#AX34O>APG^MZJ;?V'ZZ9X
M^U.R/LV_5M6\UP#_`"*P?_!$W3?K%U3IO4!T[K<N:2&^HZ-S9^B_>W^<J79+
MC_K_`$LC#OCWG?63XCVN"=BRQRS]J<(B,K$>$<,H+.9PRY?&<^/+D,X$&0G+
MBCD!/#*XM[ZX]2S<#'QGX=II<][@X@`R`/Y0<M%O4J\3HM6?EN)BECWGNYSF
MMT'\I[RN;^M=CK>A])L=JY[02?,UM3?6F]S>A])H!]KZVO</ZE;`W_SXE'")
M0PQH69S$B-ZBB?-2ADYG("2(X\<H1)](E/\`JJIS?K1]8;7OPG_9<9AB6G8T
M?R?4`]2QZ62_ZV]!C)ON^U8\PXDFQFO9^X-LK73]"QJ\;I&)56-#4UY/BYX]
M1Y_SG*UE8]>3C6X]@EEK2UP^(33S$1/A&.'M`U5>KA_O?O+X\G.6,3.;)[Y'
M%Q<7I$_W>#]QS&?63%LZ)9U9C2?2`;93.HL):P,G]W<]OO\`W$EQG3WO'2^J
MXT^US:7?-MU;/^_I*;[I#BK_`%G_`(WP>YPM;_267@XM/YF]O\M[OM<3_]'N
M/KC]9*_J_P!(?>T@YETUXC#W>?\`"$?N4_37DGU=Z-D_6/KE>*7.<+'&W+N.
MI#)W76%W[[]VUO\`PCUV'U^Z7@Y'66V]8ZV,(.K_`%3'^RW6-;6#[HMJW,>]
MUG\XM7_%QB?5[%HRV=,SF]1RRYIOM])])#/\$QM=XW;-V_Z*M8Y".,\%RR'>
M@=&OD!E,<51@.YW<7_&9]5:L6NCK'3Z@RBMK,?)K:-&AHV8]O_HE_P#UI!_Q
M8_6?[)E'H>6^,?*=NQ7'AMI^E5_5O_\`/O\`QB]'ZP.GGI>4.ID-P34[[07<
M!D>[CW;OW-J\@9T3ZK>JWT/K)[]P]*,/(W3/Z/;M'TTHR!Q&.6Q^[(@JE&L@
MECH_O1M]K7*_XS/_`!)9'_&4_P#5M71X3,BO$I9E6"Z]K`++0TL#G`?3],EV
MS<L7Z]X^%D_5RZK.RQ@T%]9=D&MUL$/;M;Z57O\`<H,>DX^89IZPEY%\]_Q8
M_P#BLK_XBW\C5["_Z#O@5YK]0^F=!QOK$RW!ZR,^\56`4#&MJD$#<[U+?9[5
MZ6[Z)[:<I_,&Y]=NHI9@%0^O35^>,6QM6=3:_1E=S7NC71K@YR]=_P#'-^J?
M^FM_[:?_`'+ST]$^JFX_]DC>3_VCO3?L3ZI__/(W_P!@KU/E]J5<9([:2'_<
ML./W(WP@'Z@OH?\`XYWU3_TUO_;3_P"Y85?7,*[ZRLZS02[$?:'!Q!!V[?1>
M[8?W5S/[$^J?_P`\C?\`V"O72="Z?]5Z::O5ZL,O'#'@@46UDSN]S2X':YCD
M</L1XR#*5P((`)]/^*P<['/,8AZ8D98F)E*,?5T_2]3Z0Q[+&->PAS7"6N!D
M$'N%QGUURVY>;C=.QCZEE9.X-U][]K65_P!95:^GV!COV;U6XXGE5D@1_P!:
MJ=6K_P!6<;ZO49S3]L^U]0,^F',>QK3^=M]5ONM3<0QXY<<9^[+7VX1B>*_Z
MRN8EGS8_;GC]B!(]W+.<>",0?T5OKI1]GZ7TZC_1>S_-8UJ?ZR83[OJWT_)8
M)^S5U[X[->QC=W^>UBO_`%QQ\*^C&&7EC#:U[BUQK=9N,<17]%:N*W&;TJIM
MCVV8S:&ASW"&N8&#W.:_Z+7,2CDD(82(F4XSF2*.O[R)X82R\R)2C#'+'CB)
M<4?37R&0:GU7ZE5G=*I:'#UL=HJM9W&T;6._MM5GK'4J>FX%F18X!T$5-[N>
M?HM"XVW!Z2[+W]#ZD^MYXJ%5Y</ZEE->_8F=T_"&0T]<ZI88_--5^XC^2^^K
MV_YB:88#/C]RHWQ&'">/^XOCEYL8QC&&Y@<(R\4?:_VB'`Q+!]7^J9SM&N]*
MIA\2+:WO_P"^)+MO\C?L;_!_LOT^?S=O_5;]W_7/4_EI*;W\G%?M3_G.*N']
M#V^#A_O?IM;[IAX*]_'7L\%\0_G/=]SC_N<?ZM__V?_M$9A0:&]T;W-H;W`@
M,RXP`#A"24T$)0``````$``````````````````````X0DE-`^T``````!``
M2`````$``0!(`````0`!.$))300F```````.`````````````#^````X0DE-
M!`T```````0```!X.$))3009```````$````'CA"24T#\P``````"0``````
M`````0`X0DE-!`H```````$``#A"24TG$```````"@`!``````````(X0DE-
M`_4``````$@`+V9F``$`;&9F``8```````$`+V9F``$`H9F:``8```````$`
M,@````$`6@````8```````$`-0````$`+0````8```````$X0DE-`_@`````
M`'```/____________________________\#Z`````#_________________
M____________`^@`````_____________________________P/H`````/__
M__________________________\#Z```.$))300````````"``$X0DE-!`(`
M``````0`````.$))300(```````0`````0```D````)``````#A"24T$'@``
M````!``````X0DE-!!H``````TD````&```````````````N````E@````H`
M50!N`'0`:0!T`&P`90!D`"T`,0````$``````````````````````````0``
M````````````E@```"X``````````````````````0``````````````````
M```````0`````0```````&YU;&P````"````!F)O=6YD<T]B:F,````!````
M````4F-T,0````0`````5&]P(&QO;F<``````````$QE9G1L;VYG````````
M``!"=&]M;&]N9P```"X`````4F=H=&QO;F<```"6````!G-L:6-E<U9L3',`
M```!3V)J8P````$```````5S;&EC90```!(````'<VQI8V5)1&QO;F<`````
M````!V=R;W5P241L;VYG``````````9O<FEG:6YE;G5M````#$53;&EC94]R
M:6=I;@````UA=71O1V5N97)A=&5D`````%1Y<&5E;G5M````"D53;&EC951Y
M<&4`````26UG(`````9B;W5N9'-/8FIC`````0```````%)C=#$````$````
M`%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<````N
M`````%)G:'1L;VYG````E@````-U<FQ415A4`````0```````&YU;&Q415A4
M`````0```````$US9V5415A4`````0``````!F%L=%1A9U1%6%0````!````
M```.8V5L;%1E>'1)<TA434QB;V]L`0````AC96QL5&5X=%1%6%0````!````
M```):&]R>D%L:6=N96YU;0````]%4VQI8V5(;W)Z06QI9VX````'9&5F875L
M=`````EV97)T06QI9VYE;G5M````#T53;&EC959E<G1!;&EG;@````=D969A
M=6QT````"V)G0V]L;W)4>7!E96YU;0```!%%4VQI8V5"1T-O;&]R5'EP90``
M``!.;VYE````"71O<$]U='-E=&QO;F<`````````"FQE9G1/=71S971L;VYG
M``````````QB;W1T;VU/=71S971L;VYG``````````MR:6=H=$]U='-E=&QO
M;F<``````#A"24T$*```````#`````$_\````````#A"24T$%```````!```
M``(X0DE-!`P`````"\0````!````E@```"X```'$``!1.```"Z@`&``!_]C_
MX``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``?_N``Y!9&]B90!D@```
M``'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.
M#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#/_``!$(`"X`E@,!(@`"$0$#$0'_W0`$``K_Q`$_```!!0$!`0$!`0``````
M```#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$``@,$!08'"`D*"Q``
M`00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B
M,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8G
ME*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"
M!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"
MDD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25
MQ-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_
M`/5"YHT)$_%<Y]>OK'D=!Z,V_"`.3D6"FM[AN:S1SW6;?SG;6>Q8?^-#ZMFZ
M@=>Q`?5H`9F-;^=7^9=_UG\__@_^+7)_5#(PLJ]_U?ZL7'`ZDYNQP,&K);I1
M=6X[MN^?14^/$#$3OB`^:-,,\A!X*J_ED[WU(^O76\KK=/3>IV_:Z<LEK7%K
M6N8\-<]I'IM9[';?<O3-[/WA]Z\UZUT3I/U%PGY>+=9D=7RPZC"?9`])KAMO
MO8U@;[V5NV;_`.6N:^IWU>M^L'5V8[BX8=,69;Y/T)TKG]^[Z*?/'"=SB>"`
M';=;&<H5`^J1\=GV_<WQ'WI;V?O#[UYC]??JSUS-Z\+>F8-EN*S'JK8:X#1M
MW>P>YOT5RF=]6_K#T[&=E9V';10T@.L<1`+CM;]%Q3(X(R`/N"ST72S2B2.`
MFNK[SO9^\/O2WL_>'WKY\P,#/ZED#%P:GY%Y!<*VG6!](^XA:1^IGUM&IZ;?
M][?_`":<>6`T.0#^7FM',$ZB!+[CO9^\/O4E\\]/+OVCB@D_S]??^6U?0RCR
MXO;K6[9,63CO2J4FD3$Z^"=<4PG_`)^D3IZA_P#/2&+%Q\>M<$3/_%69\_M>
MWZ>+W,D<6]</'^D]JDDDHV=8D#DPG6']:.BY?5ZL=F*YC34YQ=O)&A`&FUKE
MJ8%#\?"QZ+(+ZJV,<1Q+0&F$\QB(1D)7(DW']UCC.9R2@8$1B`8Y+TG?1L))
M))C(I))))3__T/4[*V6UNJL:'UO!:]IU!!$.:5X=];?J_;]7NLOQF3]FL_2X
M=G?83]'=_I*7>Q>YKRW_`!I]=Q\O+IZ/0UKW81+[[N2'N$>@QW]3W6_V/]&I
M^6,N.AL=V'F`."SN-GENJ]6ZI]8\^A^1-V1LKQZ:V]R/;[1^_=9^D>O8/JE]
M7:OJ_P!(9BZ.R;/TF58/SK#^:/Y%7T&+QGHO4[>D=5QNHUL#W8[]Q8X<M(VO
M;_)W,=['KWG`SL;J.%3FXKM]&0T/8[R/8_RF_1<I.:L",0*@LY>B92)N387*
M_P",S_Q)9'_&4_\`5M75+E?\9G_B2R/^,I_ZMJKXOYR/F&?)\DO(O#?XL?\`
MQ65_\1;^1J]A?]!WP*\>_P`6/_BLK_XBW\C5["_Z#O@5)S7\Y]`Q\O\`S?U+
M\]X'_*6-_P"&*_\`JVKZ&7SS@?\`*6-_X8K_`.K:OH9/YO>/U6\MM+S4N`ZC
MG#I_UNOS"W?Z3B0P:235L;_TG+OUP>30S(^N_I/$M-[21X[6-L_[ZER=<63B
MU'MROR8/B7%PX>$U+WH<)_K>JFW]A^NF>/M3LC[-OU;5O-<`_P`BL'_P1-TW
MZQ=4Z;U`=.ZW+FDAOJ.C<V?HOWM_G*EV2X_Z_P!+(P[X]YWUD^(]K@G8LL<L
M_:G"(C*Q'A'#*"SF<,N7QG/CRY#.!!D)RXHY`3PRN+>^N/4LW`Q\9^'::7/>
MX.(`,@#^4'+1;U*O$Z+5GY;B8I8]Y[N<YK=!_*>\KF_K78ZWH?2;':N>T$GS
M-;4WUIO<WH?2:`?:^MKW#^I6P-_\^)1PB4,,:%F<Q(C>HHGS4H9.9R`DB./'
M*$2?2)3_`*JJ<WZT?6&U[\)_V7&88EIV-'\GU`/4L>EDO^MO08R;[OM6/,.)
M)L9KV?N#;*UT_0L:O&Z1B55C0U->3XN>/4>?\YRM96/7DXUN/8)9:TM</B$T
M\Q$3X1CA[0-57JX?[W[R^/)SEC$SFR>^1Q<7%Z1/]W@_<<QGUDQ;.B6=68TG
MT@&V4SJ+"6L#)_=W/;[_`-Q)<9T][QTOJN-/M<VEWS;=6S_OZ2F^Z0XJ_P!9
M_P"-\'N<+6_TEEX.+3^9O;_+>[[7$__1[CZX_62OZO\`2'WM(.9=->(P]WG_
M``A'[E/TUY)]7>C9/UCZY7BESG"QQMR[CJ0R=UUA=^^_=M;_`,(]=A]?NEX.
M1UEMO6.MC"#J_P!4Q_LMUC6U@^Z+:MS'O=9_.+5_Q<8GU>Q:,MG3,YO4<LN:
M;[?2?20S_!,;7>-VS=O^BK6.0CC/!<LAWH'1KY`93'%48#N=W%_QF?56K%KH
MZQT^H,HK:S'R:VC1H:-F/;_Z)?\`]:0?\6/UG^R91Z'EOC'RG;L5QX;:?I5?
MU;__`#[_`,8O1^L#IYZ7E#J9#<$U.^T%W`9'NX]V[]S:O(&=$^JWJM]#ZR>_
M</2C#R-TS^CV[1]-*,@<1CEL?NR(*I1K()8Z/[T;?:URO^,S_P`261_QE/\`
MU;5T>$S(KQ*695@NO:P"RT-+`YP'T_3)=LW+%^O>/A9/U<NJSLL8-!?679!K
M=;!#V[6^E5[_`'*#'I./F&:>L)>1?/?\6/\`XK*_^(M_(U>PO^@[X%>:_4/I
MG0<;ZQ,MP>LC/O%5@%`QK:I!`W.]2WV>U>EN^B>VG*?S!N?7;J*68!4/KTU?
MGC%L;5G4VOT97<U[HUT:X.<O7?\`QS?JG_IK?^VG_P!R\]/1/JIN/_9(WD_]
MH[TW[$^J?_SR-_\`8*]3Y?:E7&2.VDA_W+#C]R-\(!^H+Z'_`..=]4_]-;_V
MT_\`N6%7US"N^LK.LT$NQ'VAP<00=NWT7NV']U<S^Q/JG_\`/(W_`-@KUTG0
MNG_5>FFKU>K#+QPQX(%%M9,[O<TN!VN8Y'#[$>,@RE<""`"?3_BL'.QSS&(>
MF)&6)B92C'U=/TO4^D,>RQC7L(<UPEK@9!![A<9]=<MN7FXW3L8^I963N#=?
M>_:UE?\`656OI]@8[]F]5N.)Y59($?\`6JG5J_\`5G&^KU&<T_;/M?4#/IAS
M'L:T_G;?5;[K4W$,>.7'&?NRU]N$8GBO^LKF)9\V/VYX_8@2/=RSG'@C$']%
M;ZZ4?9^E].H_T7L_S6-:G^LF$^[ZM]/R6"?LU=>^.S7L8W=_GM8K_P!<<?"O
MHQAEY8PVM>XM<:W6;C'$5_16KBMQF]*J;8]MF,VAH<]PAKF!@]SFO^BUS$HY
M)"&$B)E.,YDBCK^\B>&$LO,B4HPQRQXXB7%'TU\AD&I]5^I59W2J6AP];':*
MK6=QM&UCO[;59ZQU*GIN!9D6.`=!%3>[GGZ+0N-MP>DNR]_0^I/K>>*A5>7#
M^I937OV)G=/PAD-/7.J6&/S35?N(_DOOJ]O^8FF&`SX_<J-\1APGC_N+XY>;
M&,8QAN8'",O%'VO]HAP,2P?5_JF<[1KO2J8?$BVM[_\`OB2[;_(W[&_P?[+]
M/G\W;_U6_=_USU/Y:2F]_)Q7[4_YSBKA_0]O@X?[WZ;6^Z8>"O?QU[/!?$/Y
MSW?<X_[G'^K?_]DX0DE-!"$``````%,````!`0````\`00!D`&\`8@!E`"``
M4`!H`&\`=`!O`',`:`!O`'`````2`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S
M`&@`;P!P`"``0P!3`````0`X0DE-!`8```````<`"`````$!`/_A%_EH='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O`#P_>'!A8VME="!B96=I;CTG[[N_
M)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^"CQX.GAM<&UE=&$@
M>&UL;G,Z>#TG861O8F4Z;G,Z;65T82\G('@Z>&UP=&L])UA-4"!T;V]L:VET
M(#,N,"TR."P@9G)A;65W;W)K(#$N-B<^"CQR9&8Z4D1&('AM;&YS.G)D9CTG
M:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R<@
M>&UL;G,Z:5@])VAT='`Z+R]N<RYA9&]B92YC;VTO:5@O,2XP+R<^"@H@/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70])W5U:60Z839F-S%A9C(M,C8U-2TQ
M,61F+3AE-3$M8C@W,C0S9F$Q-S$Q)PH@('AM;&YS.F5X:68])VAT='`Z+R]N
M<RYA9&]B92YC;VTO97AI9B\Q+C`O)SX*("`\97AI9CI#;VQO<E-P86-E/C$\
M+V5X:68Z0V]L;W)3<&%C93X*("`\97AI9CI0:7AE;%A$:6UE;G-I;VX^,34P
M/"]E>&EF.E!I>&5L6$1I;65N<VEO;CX*("`\97AI9CI0:7AE;%E$:6UE;G-I
M;VX^-#8\+V5X:68Z4&EX96Q91&EM96YS:6]N/@H@/"]R9&8Z1&5S8W)I<'1I
M;VX^"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70])W5U:60Z839F-S%A
M9C(M,C8U-2TQ,61F+3AE-3$M8C@W,C0S9F$Q-S$Q)PH@('AM;&YS.G!D9CTG
M:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R<^"B`\+W)D9CI$97-C<FEP
M=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#IA-F8W
M,6%F,BTR-C4U+3$Q9&8M.&4U,2UB.#<R-#-F83$W,3$G"B`@>&UL;G,Z<&AO
M=&]S:&]P/2=H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C`O)SX*
M("`\<&AO=&]S:&]P.DAI<W1O<GD^/"]P:&]T;W-H;W`Z2&ES=&]R>3X*(#PO
M<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T
M/2=U=6ED.F$V9C<Q868R+3(V-34M,3%D9BTX934Q+6(X-S(T,V9A,3<Q,2<*
M("!X;6QN<SIT:69F/2=H='1P.B\O;G,N861O8F4N8V]M+W1I9F8O,2XP+R<^
M"B`@/'1I9F8Z3W)I96YT871I;VX^,3PO=&EF9CI/<FEE;G1A=&EO;CX*("`\
M=&EF9CI84F5S;VQU=&EO;CXW,B\Q/"]T:69F.EA297-O;'5T:6]N/@H@(#QT
M:69F.EE297-O;'5T:6]N/C<R+S$\+W1I9F8Z65)E<V]L=71I;VX^"B`@/'1I
M9F8Z4F5S;VQU=&EO;E5N:70^,CPO=&EF9CI297-O;'5T:6]N56YI=#X*(#PO
M<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T
M/2=U=6ED.F$V9C<Q868R+3(V-34M,3%D9BTX934Q+6(X-S(T,V9A,3<Q,2<*
M("!X;6QN<SIX87`])VAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\G/@H@
M(#QX87`Z0W)E871E1&%T93XR,#$P+3`S+3`R5#$X.C0V.C,P+3`U.C`P/"]X
M87`Z0W)E871E1&%T93X*("`\>&%P.DUO9&EF>41A=&4^,C`Q,"TP,RTP,E0Q
M.#HT-CHS,"TP-3HP,#PO>&%P.DUO9&EF>41A=&4^"B`@/'AA<#I-971A9&%T
M841A=&4^,C`Q,"TP,RTP,E0Q.#HT-CHS,"TP-3HP,#PO>&%P.DUE=&%D871A
M1&%T93X*("`\>&%P.D-R96%T;W)4;V]L/D%D;V)E(%!H;W1O<VAO<"!#4R!7
M:6YD;W=S/"]X87`Z0W)E871O<E1O;VP^"B`\+W)D9CI$97-C<FEP=&EO;CX*
M"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#IA-F8W,6%F,BTR
M-C4U+3$Q9&8M.&4U,2UB.#<R-#-F83$W,3$G"B`@>&UL;G,Z>&%P34T])VAT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\G/@H@(#QX87!-33I$;V-U
M;65N=$E$/F%D;V)E.F1O8VED.G!H;W1O<VAO<#IA-F8W,6%F,2TR-C4U+3$Q
M9&8M.&4U,2UB.#<R-#-F83$W,3$\+WAA<$U-.D1O8W5M96YT240^"B`\+W)D
M9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG
M=75I9#IA-F8W,6%F,BTR-C4U+3$Q9&8M.&4U,2UB.#<R-#-F83$W,3$G"B`@
M>&UL;G,Z9&,])VAT='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O)SX*
M("`\9&,Z9F]R;6%T/FEM86=E+VIP96<\+V1C.F9O<FUA=#X*(#PO<F1F.D1E
M<V-R:7!T:6]N/@H*/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"CP_>'!A8VME
M="!E;F0])W<G/S[_X@Q824-#7U!23T9)3$4``0$```Q(3&EN;P(0``!M;G1R
M4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@<U)'0@``````
M````````````]M8``0````#3+4A0("``````````````````````````````
M`````````````````````````````````!%C<')T```!4````#-D97-C```!
MA````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"&````!1G6%E:
M```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D```"Q````(AV
M=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M96%S```$#```
M`"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```"`QB5%)#```$
M/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L971T+5!A8VMA
M<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV-BTR+C$`````
M`````````!)S4D="($E%0S8Q.38V+3(N,0``````````````````````````
M````````````````````````````````````````6%E:(````````/-1``$`
M```!%LQ865H@`````````````````````%A96B````````!OH@``./4```.0
M6%E:(````````&*9``"WA0``&-I865H@````````)*````^$``"VSV1E<V,`
M````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````%DE%0R!H
M='1P.B\O=W=W+FEE8RYC:```````````````````````````````````````
M``````````````````````!D97-C`````````"Y)14,@-C$Y-C8M,BXQ($1E
M9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(``````````````"Y)14,@
M-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````
M````````````````````````9&5S8P`````````L4F5F97)E;F-E(%9I97=I
M;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````````+%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$`````````
M`````````````````````````'9I97<``````!.D_@`47RX`$,\4``/MS``$
M$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P`````````!````
M`````````````````````H\````"<VEG(`````!#4E0@8W5R=@````````0`
M````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4`%D`7@!C`&@`
M;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`Q@#+`-``U0#;
M`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%`4P!4@%9`6`!
M9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!\@'Z`@,"#`(4
M`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!`LL"U0+@`NL"
M]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#QP/3`^`#[`/Y
M!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P!/X%#04<!2L%
M.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&609J!GL&C`:=
M!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E!_@("P@?"#((
M1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)N@G/">4)^PH1
M"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP"\@+X0OY#!(,
M*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-^`X3#BX.20YD
M#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A$'X0FQ"Y$-<0
M]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3(Q-#$V,3@Q.D
M$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#%B86219L%H\6
MLA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`911EK&9$9MQG=
M&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC',P<]1T>'4<=
M<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@;""8(,0@\"$<
M(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-)'PDJR3:)0DE
M."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$HHBC4*08I."EK
M*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,+4$M=BVK+>$N
M%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ\C(J,F,RFS+4
M,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I-R0W8#><-]<X
M%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\93RD/.,](CUA
M/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N0C!"<D*U0O=#
M.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(!4A+2)%(UTD=
M26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE3FY.MT\`3TE/
MDT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4VU4H5755PE8/
M5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N56^5<-5R&7-9=
M)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1`
M9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K
M_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X
M=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\
M(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"](-7@[J$'82`
MA..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6B_R,8XS*C3&-
MF(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4])5?E<F6-):?
MEPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`GJZ?'9^+G_J@
M::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H4JC$J3>IJ:H<
MJH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+LL*S.+.NM"6T
MG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]%;V/O@J^A+[_
MOWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_R#W(O,DZR;G*
M.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'31-/&U$G4R]5.
MU='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZBWRG?K^`VX+WA
M1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJY>MPZ_OLANT1
M[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[]XKX&?BH^3CY
MQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@`.061O8F4`9$`````!_]L`A``!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("
M`@("`@("`@(#`P,#`P,#`P,#`0$!`0$!`0$!`0$"`@$"`@,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"``N
M`)8#`1$``A$!`Q$!_]T`!``3_\0!H@````8"`P$`````````````!P@&!00)
M`PH"`0`+`0``!@,!`0$````````````&!00#!P((`0D`"@L0``(!`P0!`P,"
M`P,#`@8)=0$"`P01!1(&(0<3(@`(,11!,B,5"5%"%F$D,Q=2<8$88I$E0Z&Q
M\"8T<@H9P=$U)^%3-H+QDJ)$5'-%1C='8RA55E<:LL+2XO)D@W23A&6CL\/3
MXRDX9O-U*CDZ2$E*6%E:9VAI:G9W>'EZA8:'B(F*E)66EYB9FJ2EIJ>HJ:JT
MM;:WN+FZQ,7&Q\C)RM35UM?8V=KDY>;GZ.GJ]/7V]_CY^A$``@$#`@0$`P4$
M!`0&!@5M`0(#$00A$@4Q!@`B$T%1!S)A%'$(0H$CD152H6(6,PFQ),'10W+P
M%^&"-"624QAC1/&BLB8U&50V160G"G.#DT9TPM+B\E5E=58WA(6CL\/3X_,I
M&I2DM,34Y/25I;7%U>7U*$=79CAVAI:FML;6YO9G=X>7I[?'U^?W2%AH>(B8
MJ+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H`#`,!``(1`Q$`
M/P#?JER>-AD>&;(4,4L9`DBEJX(Y$)4.`Z/(&4E6!Y'T/OQP`3PZKJ6I&H5Z
MI@_GG?S'.P?Y>'PYQN_^C*;#5O;?:_9&/ZEV5N;+44&=P&Q)*G;FX-T9O=M3
MC)&>@RV7H,7@3%CZ2I!IFJJA99DEBA:&60?;;E.UYNY@-K?R$6$$1E=0:%P&
M50E1D`ENXBAH*`@D$`OGSF6;EK9/JK1:W<LGAJ<$*2I):AP2*4`H14U((!!H
M$_DB?SS_`)L=M_-OKSXP_*C?_P#IVV)WY4Y[`X/.9':NU,%NWKO>&+VSF]T8
MJOQM7L[";>I<EMG*#"24E;2U<,K4_E2HADC$4D4TI>X_MKRYM_+EUO.R6WTU
MS;:25#NRR*652#K9B&%:@@BN0:D@B.^0?<#>]QWJ+:MWF\>.>H4Z44H0":C2
MJU!X$&M.(H`0=Y?^+XF]OXICK@V(^]IK@C@C_._4>\;/EY]3QJ7^(=<WRF,C
MT:\C0IY(TECUU=.NN*0721+R#5&X^A'!]^X<>MZE]1UP_C&)_P"=ICO_`#MI
MO^OOOU1Z]>U+_$.O?QC$_P#.TQW_`)VTW_7WWZH]>O:E_B'7OXQB?^=ICO\`
MSMIO^OOOU1Z]>U+_`!#KL9;%,0JY/'LS$*JBMIB2Q-@`!)<DD^_<>'7M2_Q#
MIP]^ZWU[W[KW6#[FF\O@^X@\Y-A#Y8_+<#41X]6NX7GZ?3W[RKY=5UIJTZAJ
M]*YZS^_=6Z][]U[K#-4T].`:B>&`,2%,TJ1!B/J`7902+^]@$\`3UHLJ_$P'
M6165U5T971@&5E(964BX96%P01^?>N&#QZ\""`0<=<O?NM]>]^Z]U[W[KW7_
MT+`/^%/W\MRKWSL2@_F'].XVK&\.L<7CMJ?(O$8?[A)=P]913?;;9[)DAI2I
MFR'7574BCR$A#,V%J$E=EBQ_,Z>S7-4-M=2\K;GH-M.Q>!FIVRGXDS_OP"JC
M^(4R6ZA[W4Y8:[M5Y@L8_P#&H@%EH,L@^%L`_"30_(@U`4]:\W\HGL'IGMG?
M.YOY;OS$K<U4_&7YEYW;*;7SE'F1C\YTW\I-MI54/4_96SLO7TV2I\-DMSTF
M1J=M5@>&2EK16TD=6DE.CJ98YZL;_;;>+G#EM43>MO1M0TXFMFH98W`IJ"T\
M0>8TL5(8CJ-N2;ZROI)N5M[).V7C#2:@&.;@CJ34`FN@X.H,`U5%.K@_FE\)
M_B7_`,)]ND]Q=R=0]E=C]K?.3OW$;NZ;^-&X-_5.W:-^EMO;AQG\,[7[9VS@
M]KX?%Q1[BV_LK,'&T^4J99'CK\I`M/'&CU`("Y>YCWWW4W&+:]PM(8.6;9DF
MN%0,?&936.-F8DZ68:M(H-*M4U"]#;>MCV3VXL)MPL9Y)-[G5HX2Q'Z8(H[J
M`/B"MI!-:%A1::NJ1/Y//\O3=?\`,C^7.W^NLK4;@I^B^N10=@?(3<T&0K8V
MBV9!7Z:'95'7-,2FY.R\C3O00,"TL-(M95@-]L09$Y^YFLN4-CEN8H8OWK+V
M6ZZ5^/%7(IE8QD^5=(\^@#R-R]-S/O*I/7Z"/NE/#'\/#BQP/S(J%(ZN0_GU
M?RS/F[WM\\:3=/Q3^+?8N]NF=O\`Q[Z=V!M[([!_@>/VMBWV@FYJ,[;QU+5[
M@Q1IX\'0S4\8C2((B%0#[C_VTYOY7VWED0;YND*;@;F5V#J2QU$'572>/KT.
M/<'E7?\`=-]6;:K!FM5A100,``</R-<>7&F:G7][S_EO_P`P;XS]=9/MSOOX
MV]L=6]:X:OQ&,RF\-RUV&_A5%7Y^OAQ>'I9AC=RY"K\F0R-0D*$1%=;"Y%_<
MH;7S7R?O5XEAMFX6TUXP)"A,D**GBH&!GJ-]RY4YFVFT>]O[%TME(!/I7AT7
M_H;HGOSY0=A4W5'Q^V3N_M3L>KQ&5SU+M#;5?",K/A\''%+E\@G\4RF.I/!0
M1SH7O*&.H!03Q[-]TO=EV2S?<-UD@@M%95U,HXM@``*2?\G17M6V[KO5S])M
ML+23T)H/0=';D_DS?S:(8Y)I?A9WLD<2/)(YK-LD*D:EW8A=XEC91^`3[#*\
M_P#M^Q"C>;2I_H$?X4Z$+<A\XJI8[7)0?ZO3HD'Q]J\BOR&Z&AFK:_4G>G4D
M4L;UM2UGC[&VXCHRF4@E74@^Q+N\$`VC=&6!`?II,A0/P-\NB#97<[OMZN:C
MQ5P1^8_S]?8^'_$G_>S[P%'6:IZ[][ZUUK&X>>8_SYJR$S2F$;^RUH3+(8E_
MYQ\E;TQZM`]7/T^OO-N>"`?=/600()?ID);2-1_W8@<:5ZY5VMW=?\G$)+4W
M,AMOK9.PLVG_`)(S'A6F#D=;.7O"3KJIU[W[KW56O\S_`.%W;7S+VMU)@NJ<
MQLO#U.Q]Q;HRV:EWGELQBH):;,8B@H:1*`XC!YMZB43TK>02+&%4@@GD>YP]
MC_<CE[VXW3?[SF&RN9X;FWC2,0I&Y#*Y)KXCI04."*YQ3S&*GWJ?9'G/WMV+
ME/;>3=XL[2XL;J627ZB2:-65XU5=)ABE)((-05&#@^1/ET1LG,=:]*=2=>;A
MEHJC/;&ZVV3M#,U&-GFJ<?/E-N;=Q^)KIJ&HJ8*:HGI):JE=HV>.-RA!*J>!
M%7,VY6^\\R\P[S:1LEK=WLTR*P`8))(SJ&"]H(#4-"1\^L@.0]DO^6N1^3N7
M-TF23<MOVNUMY70LR-)#`D;LK,`Q5F4D%@"1Q`X="Q[).A7U[W[KW7O?NO=?
M_]'?@W%M[![MV_G=J[FQ5#G=M[FP^3V]N'"9.G2KQN9P>:HI\;EL5D*64-'4
MT.0H*F2&6-@5>-R#P?;D4LD$L4\+E9D8,I&""#4$?,'(ZI)''-')%*@:)E((
M.0010@_(CKY6'\VO^7[N7^6M\RMS]8X@Y>+JC<\S=F_'+>/W%1]W-L6JR;24
MN&;+*D+_`-[.M,RG\.J74B8B*FJ^!4I[S6Y%YJAYQY?BNI0OUR#PYTQ36!QI
M_#(.X>62OX3UB;SMR[-RMOK^#46<AUQ-4\#Y$\:C(.:FE<`CH'_E-\L_D_\`
MS..^NK\SV(M;O_M239_6'077&T=M0U4[Y?(T,-)ADDQN.EEEU;G[)WK75&6R
M3KI1JRN*KH@AB5#+9=BV7DW;;Y+.D5EXDD\C,1@&IR:#M1`%4>0'F2:EV[;S
MNW-^XV8G!>YT)$JK7)`I6A)[F8DGU+?8!](K^4I_+NVU_+=^)&U>H]&,R?;V
M['AWWWWO.@1)!N'L;)4D:38G'UQC2>?:NR*'1B\6K:0\<,E2466JEOB'SQS7
M/S=OL]^05L4[(4/X8QYD?Q.>YO2H6I"CK)[E'ER+EG9X+$4-TW=(WJQ\A\EX
M#URU`6/5GOL']"CJ@K_A2_\`]NENX?\`Q)71/_OT]N^Y0]G_`/E>;#_FC-_U
M;/0`]S?^5/W'_3)_QX=:JO\`PF+_`.WKFR__`!!G=O\`[J\'[FOWE_Y4J?\`
MYZ(O\)ZB'VE_Y68?\TV_XZW7TCLO_P`6G*?]JZM_]QI?>(R?&GVCK)MOA;[.
MOCH=$_\`92W2?_BP?6'_`+\_`^\^MVSLNY5_Y19/^.'K"W9_^2W8?\U%Z^Q^
M/^)/^]GW@$.LU3UW[WUKK4-^1/>%+\;OYMO;/=E3A)]ROL7<=;58_`4\XI3E
M<QE>D:/`X:FJ:HJ[4V/_`(IE86J717D$"OH5FL#T/Y,Y4?G;[NVR<LQWJP-=
M1*"Y!.E$OS*[`8J=",%%1W%:]M>N,'N=[@6_M;]]7FOGNXV][L6$Q*0J0IDE
MDVE88E+'X5\212Y`)"@T!-!T:E>C?YTGR'I(^V:[N%^H4SL0RV"Z^C[$R?6[
MX_'5<:U%%3)M;:.(R,&.;Q%0JY:I;(#_`'>0U_<>GF?[LG*##EV/E@[F86TO
M=&!+C6P^(^+*Z%J&N84$?\%10]3.W(?WZ_<B-><)>>DV)+E=<=D+N6S,<;91
M?!MHI`II3$\GC#A(0:]8/C=_,/\`E!\7>_Z;XT?/3^(Y7$U^3QV&_OAN".@E
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M*QN)W"KXDUQ/!$=*(NE=<TST`&E%U$G2BDBD7:7='\T+^9/N?<N=Z*W..B^I
M,%DFQB5&&ST^S-M8R=E6H@Q55NZBQU?O/>6Y$HGC>K-)&*6+6I,5.LB*V4.Y
M\K^Q'LM96=ES78'=^8I4#,&032.,C6(6=888J@A-3%S0]SE6(P*V7GS[VGWH
M]SW/=?;K=%Y=Y'MY3&K)*;>)&%&"-<)&]U<3:"ID\-?#6JDI$'4'EV-G/YLW
M\O`X[LW?G9O^FSJX9"EH<W-E,_D^R]G125<Z+!0[A.>QV&WKM1<A*?%!6TSP
MP>9EC,A=EC>VQV'W?/>/Q]AVC83M6_>&3&%5+68T!):+0[P3%1ED<%M-6"T4
ML-<T;C]\C[M`M>;N8^:UYAY0$JK.7EDO8%U$!5F,R17,&L]J21E4UE5+EF"&
MV7#?S(.K]P?"/=OS&P^#R-<NQ:6BQ.[.N(:NG.9PG862S."VU0;;K*XJ(TQ%
M7F-R44\>0\?JQDWG$7D5H1`5Q[,;Y:>Z=A[9W-[$C73,\5T5?PWMU1Y&E"TU
M:@D;J8S_`**NC5I(<YDV?WF>3;_V(W7WQL[:62SL8E6>T!'BQ7CR10K;LW#2
MTLT1$M/[%Q)HU5C'_]+?X]^Z]UH5?\*G?G7UWV_VWUS\*M@8G;NX,G\<\O6;
MS[1[%^WAJ\O@M^;IP<=%#U7MW)HQ-)1T&!FAK=PH"RS5[44)"2T,H]Y.>RG*
M]U86%US+=3,HNP$CBSF-37Q6\LM54S4#4:4<'K'SW>W^WNKFTV.!0SP$L[>C
M,*:`?0"A8>;4R"A!UR?AC\G-R_"[Y3=*?)S;6`QFY<IU)N^ES]1MK-T=-/39
M_;V0HJG#[FQ5/)60RC%Y3)[7RU2E!7Q@2454\4Z$Z+&7.8]C3F#9-PV:X=HT
MN(Z!@2"#4,I^8#`$C@PJIP>HOY?W9]BWFQW-8U8Q.#0BN"*'["5)`/E6H%0.
MOK7]"]X=<?)3IKK?OCJ/.Q;DZY[3VKC-V[6RL8"2M19",B:@R%.&=J',X:NB
MEHZZF<^2EK*>6)_4A]X)[CM]SM5_=[9>QZ;N!RC#YCS'R(R#Y@@]9DV-[!N-
MG;7]JVJWE0,I^WR/H0<$>1!'0N>T?2KJ@K_A2_\`]NENX?\`Q)71/_OT]N^Y
M0]GO^5YL?^:,W_5L]`#W-_Y4_<?],G_'AUJJ_P#"8O\`[>N;+_\`$&=V_P#N
MKP?N:_>7_E2I_P#GHB_P]1#[2_\`*S#_`)IM_P`=;KZ1^7_XM63_`.U?6_\`
MN-+[Q'3XT^T=9-O\+?9U\<_HG_LI;I/_`,6"ZP_]^?@?>?.Z_P#)$W+_`)Y9
M/^K9ZPMV?_DMV'_-1>OL?C_B3_O9]X!#K-4]=^]]:ZU.>QMC8CL?^=U+M+/4
MJ5V&K.\MG93(4,J+)#6P[6ZYP.ZQ25$;`K)2U$N$595/#1%@?K[S[V?=+C9O
MNN?O"UE\.X&V3QJU:$&:YDBJ#_%1SI\ZTZX]\S[!9<S??^_=&X0B2S;>K61E
M(J&%O90SZ6!J"I\*C`XTD];8WO`3KL)UKC_S]]F8@0?'3L&.%(\[43;]V565
M"H@DJ\/#!@\[CXI90-;+CZV>J,8)LIJ7(')]YB_='W.X^IYWV1LVFFWG4>0:
MKQN:?TAIJ?Z`ZYD?WC6QV8MO:_F55`W'7=V[&@JT8\&5`3QHC&0J.'ZC$4S4
M/?YJFX<ANSX/?R^MSY69ZC)Y[:^(RN0GE_SL]=6=4;:FJYI?4W[LU0S,W^)/
MLP^[]8P[;[M^\%A;"EM$[J@]%%Y*%'Y#'1#]\+=;C?/N_P#W<]WNV+7=S;0R
M.3Q+O8V[,3]K$GK'_-)WMD\=\'?Y?'7]-4-'BMS=>[7W9EX%9E^ZGV=U1LG&
MXA9+.%>*%MVU#V8'UA2+$<JO83;()O=;WAWAT!N;>[FB0TX">ZF9Z>A_145'
ME4=-?>[WZ]M?N]?=LY:AE9;&]VVVFD`)`9K:PM5C!\B!]2YH:Y`/$=7G_!GK
M?`]5_$?X_P"UMOP1Q4\W6.UMT9&98HXI:_/[TQ=/NS/9"H,:IY9JC*9>6S-=
MA&%6]E'O%KW.WF[W_P!P>;MRO)"TGUTL:BI(6.%C%&HKP`1!^=3Y]=`/8?E>
MPY/]G?;K9-OB"QC:K>9Z``M-<1B>9C3B3)(V<XH*T`Z'+M+8&`[5ZXWQUONB
MBAK]O[VVOFMMY2FGACF4T^4H9J83QK("JU-)*ZS0O]8Y45A8@'V&-EW6[V+>
M-KWFPF*7EK<)*A!H:HP-/L8`JPX$$@X/0[YJY>V_FWEK?N6-U@63;[^TE@=6
M`(I(A4-0^:DAE/$,`000#UI<_'S-9N#XO?/WJQ:MSB<IM3H3,21,SF./.8+Y
M,]=;9AK(H]7C22>EW$XD.F[")!>RCWTPYPLK1^>_:'F3PQ]1'/N$=:9,<FVW
M$M"?.ACQZ5/KUPK]M;Z^C]H_O'<F^+6SFMMHEIG2)(=\L800M<:A.:^9"J*X
MZ__3VFOYQ/\`,=P?\M[XD;A[!QE3CJSO7L4UNPOC_M6L,,YK=Z55)JK=X9&@
M=M<^V.N\=-_$:RZF.:?[:D8JU6A`UY"Y2GYOWV*TI3;X2'G;TC!^$?TGX*./
M$_A/05YQYDAY9V>:[+?XVX*Q#U:G&GHO$^1-`:5KU\\'^7?\.>R?YG'S=VAU
M%797<&5I]X;CR?:'R'[*J9I:S+XG8$&8BRW8N[:_)RK)KW-NBNR0H*%Y.)<O
MDH2WH#D97\V\Q6G)O+=Q?!%UI&(H(_(OITQJ!_"H%2!^!33K&OE;9;GFSF&*
M*0GPV<R2MQHM:L:GS/`$U[B*UJ>M@;_A3!_*RVSU/MWJ[YJ_'/8U'MSK[:VV
M]E=$=V;5VY1F+';;QFW,?1;6Z;W\88Q(XI?X;30;:R-1(WZXL626:25_<7>S
MG.TEY+?<N;Q<,]Y(S30.QXEB7F0_.I,BTIQDK^$=2/[I\HQPV]MOFV6X6&-5
MCD44%``%C;UX40\>"4&2>@R_X3(_S-CTUVG4?`3N'<*T_5_=6;J,UT/E,I4!
M:79W<E8FK)['2:9PM-A^TX(0])'<(F>@5$7R9%S[6>\?);;A8GFS;HJW=JH6
M=12KQ9I)3XF,9PU*TCR2`HZ1^U/-GTUP>7;Z4"WE-8B:X?\`AKP`;R&.ZE*E
MCUOQ^\8.L@^J"O\`A2__`-NENX?_`!)71/\`[]/;ON4/9[_E>;'_`)HS?]6S
MT`/<W_E3]Q_TR?\`'AUJJ_\`"8O_`+>N;+_\09W;_P"ZO!^YK]Y?^5*G_P">
MB+_#U$/M+_RLP_YIM_QUNOI'Y?\`XM63_P"U?6_^XTOO$=/C3[1UDV_PM]G7
MQLNL=QXO9W=W7.\,Y)+#@]H]P;,W3FIJ>!ZF>'#[=WWC,SE)8*:*\M3-'0T4
MC)&OJ=@%')]Y_P!]!)<[7=VT0'BR0.H\LLI`S]IZPGL+B.UW2UN)32-'!/V=
M?18_Z";/Y3P)`[+[:87-B.C-_@$7/(#8X-8_X@'WB@/9OG<@'Z6W'_-Y>LEC
M[I<I?\I$O^\C_H+KW_03;_*>_P"?E=M?^B-W]_\`6_WO_6;YW_Y1K?\`YS+U
MK_72Y3_Y2)?]Y'_0755N"^<'2^^OYDFW_F[L#)9G*=&[@[/PF;I,QDL%78/,
MKM:7:=)UYN+*5&`R*1Y&F;%2K5S")U$DL4(*B[K[S&V[D?=[_P"[X.2FCC&]
M-8R!5U`J9%N'FC74,58JJUX`G.*]<G>;_<79.5/ON7//UU*W[A@W:W\5Z96&
M2SB@E?3Q.A79J#)`H,FG6Z)ALSB]PX?&9[!Y&@S&&S-!2Y3%97%5<-?C<ECZ
MV%*FCKJ"MIV>"JI*J"17CD0E65@0??.JX@GM)YK:[@>*YC8JZ."K*RFC*RG(
M(."#D'KL]9WEIN%I;7]A<QS6,T:O'(C!D=&`971@2&5@0002"#4=:S'\ZOMJ
MA[F[KZ4^,_653!NW<^SJK)1YS&X8BNFA[![`K,+A<!M1Y:=I%_BU+14(DG@%
MVA^]0/9@RC-K[L>P/RYROS3S[O:-;V%PJ^&TG:#;6ZO)),*Y\-F-%8X;02N,
MGEA]^[FV'GGGOV]]IN5)TO=XM9'\:.(ZRMU=/%'%`Q%0)%5*LG%?$750XZ6_
M\Y[9:];_`!@^&/7J/Y5V,\VT1+JU^4[<Z[P>(:779=7D>D+7L+W]D?W9=S;>
M_<3W+WEE(:[B$U#Y>+=2/3\M5.A!]^G8TY8]HO9'EM&!7;V%M7U\"TABK^>F
MO4O^9%TWF=\_RXOAWVI@Z2HK_P#0UU[UG_>6&F0R-1[1WWUKM+&56:F18V<T
M^.S^*QT;M<+''4N[>E25M[)\S6FT^]7N3R_=RA/WG>7/A5\YH+B5P@S^*-Y#
M\RH`R0.G_O1\B;AS']UOV3YNVV!I&V+:[!I@*DK;W5E;QO)0`UT2QP`^BLS'
M`)%D7\L#Y(;:[]^*?7>,@RU+)OSJ;;N&ZWWW@3)%'D**3;5%'BL!F32ZS*^,
MW#@J.":.<*(VG$T0]43@0W[X\F7_`"C[@;W++;D;3N$SW-NXKI996U2)7AJC
MD+*5K4+H;@PZR=^ZI[I;1[E>T/+,5O=)^_\`:+:.RNX<!T:!1'%)IJ24FB5&
M5^!?Q$^)&Z'7Y@_)':/Q<Z)WKV5N3)T5/ETP^1Q>P\'+-"*_=.]ZZCEAP.(Q
MU&\L<M6B5;K/5LEQ!1Q22M8+R%?;SDK=.?>:]KV';H&,+2*T\E#IA@4@R.YX
M#%56I&IRJCCU('O/[G;)[2^WV_\`-F[W:)<I`Z6L9(USW3J1%&BUJW=1I"/@
MC5W.%ZU4NA.J=R4GP`^=GR"R,5128O+1](==[7KY4T19?*47?_7.Y-TUE.&7
M]V+&U@Q\6M3I\SR)RR&V?'-W,-B_N_[3\GP.&N4^NN)DIA%-A<1PC_;#Q200
M**%/!NN0'MWR9O%O]VO[P?N5=PNEC<?NJTMW.#(R;O937#`4R$(A`8=I8N.*
MD#__U#+_`,_'XP=%]D?,G%;O^;/\T.C^.5-D=A4T7Q_ZA/PR^0G9NWMM=<45
M::7.3T.^-A565VOGMT9C=<<M5F75H*N+RTD;P1P)2ZLA_:[>=SL]@D@Y=Y--
MXXE/CR_5P1LSG*@HX#!0M`O$&C$&NKJ#_<?:["[W6*7>^:!:0Z!X4?TT\@`S
M4ZD)4DFI-*$8KBG1_?\`A.1U5_+VZDV1\@L#\4OE3@OEMW;7Y[;>5[9W\.H.
MP^E,S@]@/!6TVP-K83:7:&,H\W4;;ILI3Y*IK*VBGJ:>;(5"+/XRE,GL+^[5
M]S9?76UR;YLC6.VA6$2>*DP+X+LS1DKJII"@@$`'36K="'VTM.7+.RO8]GW9
M+R[+`N_AM$P7\*A7`;36I)R*D5X#J]CY>0?'ZJ^+_?--\JZW#X[XYU'5^[8.
MXLAG4GDH:#8\V*GCRU;"E%25^2?+TJLKX\4<$U><@L/VJ/4>-3&FR'<UWC;#
MLRL=U$Z>$%XEZBGH*?Q5(6E=6*]#_=18G;;X;F0-O\)O$)KA:9I2IKZ4!-:4
MS3KYQ&#^$W\KAMV87^X/\[)HMPMNC%_W$7%?R^_EU/NZ+.-F8/[I+C)L9C8*
MF?<\>0-,('IHD=ZP*8T4E5&6\O,7.OT\GU7MU^EH.NM]:Z:4[JU)[:5K7RX]
M8RV^Q\J_6QFQYX'U&OL"V=R6K7`&FF?LI\NOI;],8?L+;W4W76![7WGC^QNR
M,-L_!8S>>_L9M>LV32[SSM#00TU9N<[1K\EEJO;E7FVC%144;5$@@J)'5=*@
M(N']\]M+>W4EG`8K5I&*(6#E%)PNH`!J<`:9'64-FLZ6MNES*)+@(`S`%=1I
MDZ2217C2O59'\]7K_IKLW^73V5M'OOO^E^,G6M9OKJ2IRO;E9UEO7MZ##UU!
MO_"U6'QAV1U^DFYJ]L]D8XZ431#QTQD\DGH4^QE[:W6XV?-EG/M>UF\NQ'*!
M$)$BJ"AJ=;]HT\:'CP'08Y[M[*ZY:O8=PW`6MJ2E9"C24[A3M3N->&.'6OE_
M(<^-/P-ZO_F&[7W9\?OYEN(^4'8T/4W:M!2=3TGQ)[]Z=GK,374&)7+9T;U[
M"IX]M0)@XHU8TSMYJCR6CY4^Y1]SMWYHO>5Y(-TY0-E9^/&3(;J"7()HNB/N
MR:9X"G4<>W6V<NVF^F7;>9EN[CPVH@MYHO(YU/CA7'6\'DE1\=D$DE\$;T54
MKS%&D$*-!(&E,:^I_&#>PY-K>\<EKJ73\5>IV:FDUX4Z^7E6?"C^5&U;6M)_
M.PV_%(U;6-)%_P`-\_+*3Q2-4REXO(*0!_&Q(U#@VN/>9R<Q<\:%I[=-2G_*
M=:]8FR;%R?K:O/25_P">.YZC?[)-_*@_[W9X#_TWO\L__J3W;^L7//\`X3I_
M^RZUZK^XN3O^F[3_`+([GKW^R3?RH/\`O=G@/_3>_P`L_P#ZD]^_K%SS_P"$
MZ?\`[+K7KW[BY._Z;M/^R.YZNJ^#'Q\_E@;&VEL9]T_S!,/WIU=1[,WY15=+
M3_&COKJ^OS,>2AW!34N9P5=G<5D*S$Y[;F8JEJ*.+[>::HGIE5(W5])%]YS+
M[S7/*FW6G*_MI):W@EB,=P;^SE4Z9M3H\-4/AR`,CEF4*I)+"@/6(^\<F?=I
M@]Y^:MW]Q/>:">U>&5;C;SM>X1/&6LU1'BNPKQF:,Z)HPB.S,`@4FJDPV"^/
MVX8<1EU^+/SV[@R'1S&H:*7%=(?.+$8Z#'-+(6@J8.O^K,UM*LFA!832T\E.
MLK@DQQWTA3><WV#7=I_K@>TNV)S;CXK[9'8M04(^HNDE4'\(;508U-Q(:VWV
MWWQ-NNO]:#[Q._R>WI9M&C:^:8T5"34$6FWRP.P&&92@8U.E*T!N/Y:?6G\O
MG8?=V'G7Y(T_>WR=R$N639U)F^M^S.O,!MW+)25#9HX*+?NVZ&++[WEIS4*L
M]76+5Z=8IZ9)-;>X_P#?+>_=_=^6+E9^2CM'(:!/&*7-O<R2K4:/$,$C%(*T
M.E$T5IKD*T'4O_=3Y7^[=R[SU`UM[G+S#[N2&7P!-97MG'"P5O%$(O(4$ER5
MU#6[^)35X<2G42:[^<)U]TOV!L7I:D[G^05+\?\`'8[=^Z:C"9:JZPWMV<-P
MULV!I8JG'I0[*C>HQC4<`$IEG(1P=*^KW'OW=-WYDVC?^9I>6.43N]R]G$)$
M%U#:^&HD)5M4W:^HU%!D4KPZEW[ZO+?(G,?+')$//7N0O+=K%?3-%(UA=7_C
M.8E#)HM>Z/2*'4^#6@SU8%UEC^N,5\5]A8O<&X,#NOJ?'=$;1H<IN?/XN3";
M<W%L&CV%CJ>7.9C#YX>7%XO+X&/[B:GJP)((Y"DGJ4^XAWJ7>;CGG>YX;66W
MWZ3=Y66*)M<D4YG)$:/'\;I)159/B(JO62O*-OR[9^U'*MI<[A!><J1<O6R-
M/*GA0SVBVB`S212YCCDA&MXY<HI*OP/6LCN;H_XF9;M>3-?`;YK;TVIG:^6I
MFHMCT/3WRFRFX<'3O,IE@P&[>N>MZS<E9@$F*A(ZJDE9$`UU$O!]YR6?-/N'
M;<O?2^\'MC:7-BI4&=[S:T1S3M,D-S<+&)>)JCJ2:T1>N5&X<@^SM]SI/?\`
MW;_??<;'=Y"Y6TAVW?9'CJ:LL-S963RF$"H`:-R%`U2/QZBY+H+I6+L+%5GS
MX^=W8]0*5#,N!R?2?RR&[LO1(T334F,W%VIUA3/B*&4@+*]+05+$6TZ&LPM:
M\W<SML5Q%[/>T]@L3$#Q$OMJ\)'S0O%:W)UM2NG7(M.-",=)[WVZY$BYDVVY
M^\I]X/=Y%3*P2[7S`)I$!%52>_L%\-"::BD+^@*GN&R`J?#;_9-)(TEZ^_V3
MC_1X$EG42_W3_NGYD`ED`C_C/]Y/XWI/*?QG^-6X^^L/>&?_`#$C_7(K2^_U
MR?K?^;WC>@_!X7A^GZ'@?\)ZZ>`>RW^LJ0&VW_65_=F3_P`1OIO7_?GC>)\O
(JOJO^7CK_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
